CCL3 Secreted by Hepatocytes Promotes the Metastasis of Intrahepatic Cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (mA) Modification
Overview
General Medicine
Authors
Affiliations
Background: Intrahepatic cholangiocarcinoma (ICC) is a malignant disease characterized by onset occult, rapid progression, high relapse rate, and high mortality. However, data on how the tumor microenvironment (TME) regulates ICC metastasis at the transcriptomic level remains unclear. This study aimed to explore the mechanisms and interactions between hepatocytes and ICC cells.
Methods: We analyzed the interplay between ICC and liver microenvironment through cytokine antibody array analysis. Then we investigated the role of N6-methyladenosine (mA) modification and the downstream target in vitro, in vivo experiments, and in clinical specimens.
Results: Our study demonstrated that cytokine CCL3, which is secreted by hepatocytes, promotes tumor metastasis by regulating mA modification via vir-like mA methyltransferase associated (VIRMA) in ICC cells. Moreover, immunohistochemical analyses showed that VIRMA correlated with poor outcomes in ICC patients. Finally, we confirmed both in vitro and in vivo that CCL3 could activate VIRMA and its critical downstream target SIRT1, which fuels tumor metastasis in ICC.
Conclusions: In conclusion, our results enhanced our understanding of the interaction between hepatocytes and ICC cells, and revealed the molecular mechanism of the CCL3/VIRMA/SIRT1 pathway via mA-mediated regulation in ICC metastasis. These studies highlight potential targets for the diagnosis, treatment, and prognosis of ICC.
Liu F, Liu Q, Li X, Wang Y, Cao R, Zhang S Front Immunol. 2025; 16:1538658.
PMID: 40034695 PMC: 11873077. DOI: 10.3389/fimmu.2025.1538658.
Liver Metastasis in Cancer: Molecular Mechanisms and Management.
Xu W, Xu J, Liu J, Wang N, Zhou L, Guo J MedComm (2020). 2025; 6(3):e70119.
PMID: 40027151 PMC: 11868442. DOI: 10.1002/mco2.70119.
Srisathaporn S, Ekalaksananan T, Heawchaiyaphum C, Aromseree S, Maranon D, Altina N Cancers (Basel). 2025; 17(3).
PMID: 39941858 PMC: 11815735. DOI: 10.3390/cancers17030491.
Cai T, Dai J, Lin Y, Bai Z, Li J, Meng W J Transl Med. 2024; 22(1):875.
PMID: 39350174 PMC: 11440763. DOI: 10.1186/s12967-024-05664-z.
Landscape of mA RNA methylation regulators in liver cancer and its therapeutic implications.
Zhao J, Li G, Lu X, Zhu L, Gao Q Front Pharmacol. 2024; 15:1376005.
PMID: 38545555 PMC: 10965734. DOI: 10.3389/fphar.2024.1376005.